The American Cancer Society and a coalition of leading professional, government and non-governmental organizations have formed the National Lung Cancer Roundtable.
Columbia University Medical Center and New York-Presbyterian, in coordination with the Foundation for the National Institutes of Health Biomarkers Consortium, is launching a three-year research collaboration to develop new methods for analyzing digital images that track a patient's response to cancer therapy.
The Mikey Czech Foundation, Inc., a 501(c)(3) non-profit foundation established by Stephen and Jennifer Czech to finance medical research for pediatric brain tumors, announced a $1 million gift to Pediatric Medical Neuro-Oncology at Dana-Farber, headed by Mark Kieran.
The Feinstein Institute for Medical Research announced Jeffrey Ravetch, the Theresa and Eugene M. Lang professor and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at The Rockefeller University, as the recipient of the fifth annual Ross Prize in Molecular Medicine.
Molecular biologist Alan Bernstein is the 2017 recipient of the $35,000 Henry G. Friesen International Prize in Health Research.
The FDA Oncologic Drugs Advisory Committee March 29 unanimously recommended approval of a lymphoma treatment, to be administered via subcutaneous injection.
It's fair to say that eight years ago, when the Obama administration infused the economy with $800 billion in stimulus funding, policymakers likely did not expect the health information technology industry to evolve into fiefdoms guarded by legions of lawyers and walls of proprietary code.
FDA granted an accelerated approval to Bavencio (avelumab) for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
In a simple definition, cancer is a disease of the cells, which is caused by gene mutations. For a proportion of patients, including women with hormone receptor positive breast cancer, gene expression profiling has a substantial impact on treatment decision-making by determining which patients might—or might not—respond to particular treatment options.
